On May 27, 2014, MacroGenics Inc (NASDAQ:MGNX), and Takeda Pharmaceutical Company Limited jointly announced that they have entered into an option agreement for the development and commercialization of MGD010. This product candidate incorporates MacroGenics’ proprietary platform for Dual-Affinity Re-Targeting (DART®) to simultaneously engage CD32B and CD79B, which are two B-cell surface proteins. MGD010 is currently in pre-clinical development for the treatment of autoimmune diseases. MacroGenics Inc (NASDAQ:MGNX), net profit margin is -6.20% and weekly performance is 11.94%. On last trading day company shares ended up $20.44. Analysts mean target price for the company is $51.67. MacroGenics Inc (NASDAQ:MGNX), distance from 50-day simple moving average (SMA50) is -12.55%.
On May 13, 2014, Opexa Therapeutics Inc (NASDAQ:OPXA), a biotechnology company developing Tcelna® (imilecleucel-T), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), reported it has reached the targeted enrollment in its Phase IIb clinical trial in Secondary Progressive Multiple Sclerosis. 180 patients with Secondary Progressive MS have been randomized in the Phase IIb “Abili-T” clinical study of Tcelna. The Company will also allow patients who are currently in the screening process at the time of full enrollment and who meet the trial’s entry criteria to also be enrolled in the trial. Opexa Therapeutics Inc (NASDAQ:OPXA), advanced 7.79% in last trading session and ended the day on $1.55. OPXA, return on assets is -97.20%. Opexa Therapeutics Inc (NASDAQ:OPXA), quarterly performance is -16.10%.
Netlist, Inc. (NASDAQ:NLST), CEO Chun Hong sold 350,000 shares of Netlist stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $1.29, for a total value of $451,500.00. Following the completion of the transaction, the chief executive officer now directly owns 85,568 shares in the company, valued at approximately $110,383. Netlist, Inc. (NASDAQ:NLST), shares moved up 22.22% in last trading session and was closed at $1.32, while trading in range of $1.10 – 1.51. Netlist, Inc. (NASDAQ:NLST), year to date (YTD) performance is 78.78%.
Ventrus Biosciences Inc (NASDAQ:VTUS)‘s stock had its “hold” rating restated by equities researchers at Cantor Fitzgerald in a research report issued on Wednesday. They currently have a $1.25 price objective on the stock, down from their previous price objective of $2.50. Cantor Fitzgerald’s price target would indicate a potential upside of 32.98% from the stock’s previous close. Ventrus Biosciences Inc (NASDAQ:VTUS), ended the last trading day at $1.27. Company weekly volatility is calculated as 15.27% and price to cash ratio as 1.10. Ventrus Biosciences Inc (NASDAQ:VTUS), showed a negative weekly performance of 47.67%.
On May 14, 2014, Suntech Power Holdings Co., Ltd. (ADR) (OTCMKTS:STPFQ), announced that the administrator of Suntech Power International Ltd. (“SPI”), the Company’s principal operating subsidiary in Europe, has called for a meeting of the creditors of SPI on June 10, 2014 to consider a proposed dividend agreement to resolve the claims of SPI’s creditors. Suntech Power Holdings Co., Ltd. (ADR) (OTCMKTS:STPFQ), on last trading day company shares ended up $0.287.